Tagged phase-3
Neumentum Announces Initiation of Phase 3 Program Evaluating Its Lead Product Candidate, NTM-001, for the Management of Moderately Severe Acute Pain
NTM-001 is an Investigational, Alcohol-Free, Stable Formulation of Ketorolac in a Pre-Mixed Bag for 24h Continuous Infusion. NTM-001 has the Potential to Deliver Opioid-Level Pain Relief Without Analgesic Gaps and Reduce or Eliminate the Need for Opioids. Phase 3 Efficacy and Safety Study is Comparing NTM-001 vs. Placebo, and Includes a Morphine Arm for Assay Sensitivity in Patients with Moderately Severe Pain After Bunionectomy Surgery. Results Expected Second Half 2023.
Read MoreRecardio and FDA Reach Agreement on Pivotal Phase 3 Trial Design
Recardio Inc., a late stage clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the FDA concurs with Recardio's pivotal Heal-MI Phase 3 trial design with Dutogliptin in Acute Myocardial Infarction.
Read MoreRecardio's Positive Phase 2 Results Presented as Latebreaker at World Congress on Acute Heart Failure 2022 in Madrid
Recardio Inc., a clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the positive study results of Recardio's Phase 2 clinical study in Acute Myocardial Infarction were presented on Saturday, May 21, 2022, during the Latebreaker Session at the World Congress on Acute Heart Failure 2022 in Madrid.
Read MoreRecardio Completes Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin
Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, announced the completion of its Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction.
Read More